2-(3-bromophenyl)-4,5-bis(4-methoxyphenyl)-1H-imidazole | 36741-13-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-bromophenyl)-4,5-bis(4-methoxyphenyl)-1H-imidazole
• CAS: 36741-13-6
• 化学式: C₂₃H₁₉BrN₂O₂
• 分子量: 435.32
• InChiKey: HLBCNPPCMJYGSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  47.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  间溴苯甲醛 、 4,4'-二甲氧基苯酚酯 在 5,10,15,20-tetrakis(4-methylphenyl)porphyrinatozinc(II) 、 ammonium acetate 作用下， 以 乙醇 为溶剂， 反应 1.33h， 以90%的产率得到2-(3-bromophenyl)-4,5-bis(4-methoxyphenyl)-1H-imidazole
  参考文献：
  名称：

  锌（II）[四（4-甲基苯基）]卟啉：新型和可重复使用的超声辐射下有效合成2,4,5-三取代的咪唑的催化剂

  摘要：

  使用锌（II）（四（4-甲基苯基））使1,2-二酮或α-羟基酮与芳族醛和乙酸铵缩合反应，可有效地三步合成2,4,5-三取代的咪唑描述了在室温下超声辐射下卟啉作为新型可重复使用的催化剂。在这种方法中，α-羟基酮以及1,2-二酮以优异的产率转化为它们相应的2,4,5-三取代的咪唑。

  DOI：

  10.5012/jkcs.2011.55.5.787

文献信息

• Zinc (II) [tetra(4-methylphenyl)] Porphyrin: a Novel and Reusable Catalyst for Efficient Synthesis of 2,4,5-trisubstituted Imidazoles Under Ultrasound Irradiation
  作者：Javad Safari、Shiva Dehghan Khalili、Sayed Hossein Banitaba、Hossein Dehghani

  DOI：10.5012/jkcs.2011.55.5.787

  日期：2011.10.20

  An efficient three-component one-step synthesis of 2,4,5-trisubstituted imidazoles by condensation reaction of 1,2-diketones or α-hydroxyketones with aromatic aldehydes and ammonium acetate using Zinc (II) (tetra (4-methylphenyl)) porphyrin as a novel and reusable catalyst under ultrasound irradiation at ambient temperature is described. In this method, α-hydroxyketones as well as 1,2-diketones were

  使用锌（II）（四（4-甲基苯基））使1,2-二酮或α-羟基酮与芳族醛和乙酸铵缩合反应，可有效地三步合成2,4,5-三取代的咪唑描述了在室温下超声辐射下卟啉作为新型可重复使用的催化剂。在这种方法中，α-羟基酮以及1,2-二酮以优异的产率转化为它们相应的2,4,5-三取代的咪唑。
• IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
  申请人：Axxima Pharmaceuticals Aktiengesellschaft

  公开号：EP1532118A2

  公开（公告）日：2005-05-25
• Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections
  申请人：Salassidis Konstadinos

  公开号：US20050203155A1

  公开（公告）日：2005-09-15

  Novel imidazole compounds particularly useful against Hepatitis C Virus infections and diseases associated therewith are described. Applications of the human cellular proteins casein kinase I alpha (α), delta (δ), and epsilon (ε) as targets for medical intervention against Hepatitis C Virus (HCV) infections and diseases are also described. This invention further refers to a method for identifying compounds useful for the prophylaxis and/or treatment of Hepatitis C Virus infections and diseases, methods for treating Hepatitis C Virus infections and diseases, as well as pharmaceutical compositions useful for the prophylaxis and/or treatment of Hepatitis C Virus infections and diseases. Moreover, disclosed are antibodies, oligonucleotides and specific compounds which are effective for the detection, prophylaxis and/or treatment of Hepatitis C Virus infections and diseases. Solid supports useful for the identification of compounds suitable for preventing and/or treating Hepatitis C Virus infections and diseases are also disclosed.
• CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20200078387A1

  公开（公告）日：2020-03-12

  The present invention relates generally to chromosome maintenance and cell viability, and more specifically, to the identification of kinases the inhibition of which blocks telomere elongation. In one aspect, the present invention provides methods for treating cancer. The methods generally comprise the administration of agents that interfere with the lengthening of telomeres in cancer. In a specific embodiment, a method of treating cancer in a subject by interfering with lengthening of telomeres in cancer cells comprises administering to the cells an effective amount of an inhibitor of casein kinase 1 (CK1), wherein the administration of the inhibitor leads to progressive telomere shortening in the cancer cell, thereby treating cancer in the subject. In another embodiment, the method can further comprise administering to the cells an effective amount of an inhibitor of bromodomain-containing protein 4 (BRD4) and/or an inhibitor of the MEK/ERK pathway.
• [EN] IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS<br/>[FR] COMPOSES D'IMIDAZOLE ET PROTEINES CELLULAIRES HUMAINES CASEINE KINASE I ALPHA, DELTA ET EPSILON UTILISES COMME CIBLE LORS D'INTERVENTIONS MEDICALES CONTRE DES INFECTIONS PAR LE VIRUS DE L'HEPATITE C
  申请人：AXXIMA PHARMACEUTICALS AG

  公开号：WO2004005264A2

  公开（公告）日：2004-01-15

  The present invention describes novel imidazole compounds, which are particularly useful against Hepatitis C Virus infections and diseases associated therewith. Furthermore, the invention relates to the human cellular proteins casein kinase I alpha (α), delta (δ), and epsilon (ϵ) as targets for medical intervention against Hepatitis C Virus (HCV) infections and diseases. In addition, the present invention refers to a method for the identification of compounds which are useful for the prophylaxis and/or treatment of infections and diseases caused by Hepatitis C Virus, methods for treating Hepatitis C Virus infections and diseases, as well as pharmaceutical compositions useful for the prophylaxis and/or treatment of Hepatitis C Virus infections and diseases. Moreover, disclosed are antibodies, oligonucleotides and specific compounds which are effective for the detection, prophylaxis and/or treatment of infections and diseases caused by Hepatitis C Virus. In addition, the present invention describes solid supports useful for the identification of compounds suitable for preventing and/or treating infections and diseases caused by said Hepatitis C Virus.